Home » Gene Therapy for Leber Congenital Amaurosis
Gene Therapy for Leber Congenital Amaurosis
Leber congenital amaurosis (LCA) is an inherited retinal disease that causes severe visual impairment in infancy or early childhood. Current research on a gene transfer therapy may offer hope to people with a form of this disease.
Interactive Timeline The Research Road: Gene Therapy for Leber Congenital Amaurosis
View the text-only timeline.
Study Results
- Gene Therapy One Year Later: Patients Healthy and Maintain Early Visual Improvement, August 2009
- Promising Results in Phase 1 Gene Therapy Trial for Blinding Disease, September 2008.
- Selected Bibliography on LCA and RPE65
Background Information
- Canine Study Puts Gene Therapy for X-linked Retinitis Pigmentosa in Sight
- Scientists Refine Gene Therapy for Rare Congenital Blindness
- Backgrounder: Human Gene Transfer Therapy for One Form of Childhood Blindness
- The Gene Therapy Journey: From Bench to Bedside
- NEI Funding of Basic and Preclinical Studies Prior to the LCA Gene Therapy Trial
- NEI Statement on Clinical Trial of Gene Transfer Therapy for Childhood-Onset Blindness, November 2007
Other Useful Links
- NEI Photos, Images, and Videos: Leber congenital amaurosis
- ClinicalTrials.gov: Phase I Trial of Gene Vector to Patients with Retinal Disease Due to RPE65 Mutations
- NEI Molecular Mechanisms Section, Laboratory of Retinal Cell and Molecular Biology
- NEI Ophthalmic Genetics and Visual Function Branch
- MEDLINEPlus: Genes and Gene Therapy
